Another good news: Phase-3 trial data showed real power of indigenous covaccine, The Lancet also admitted iron


There is another good news for India’s indigenous vaccine ‘Covaccine’. First approved by the World Health Organization and now The Lancet has rated Bharat Biotech’s Covaccine as ‘highly effective’. A new study in the medical journal The Lancet said on Thursday that the Kovid-1919 vaccine made by Bharat Biotech is ‘highly effective’ and is completely safe. The Phase III trial data of Covaccine does not mention any safety concerns.

The Lancet said Bharat Biotech’s Covaccine has been found to be 77.8% effective against symptomatic corona patients. The Lancet said in a statement that the vaccine produced a strong antibody response two weeks after both doses of the vaccine were given. The medical journal said that no vaccine-related deaths or any serious adverse events were reported during the Covaccine trial involving 24419 volunteers aged 18-97 years in India between November 2020 and May 2021.


The Lancet has released data for Phase III of Bharat Biotech’s Covaccine. According to this, India’s indigenous vaccine is not only safe and effective against Kovid-19, but it is also 65.2 percent effective against the delta variant. Not only this, the vaccine is 93.4 percent effective against severe symptomatic Kovid-19. Let us tell you that Covaccine has been developed jointly by Bharat Biotech and Indian Council of Medical Research.

Let us inform that recently Kovaccine has been included in the Emergency Approval List of the World Health Organization and its use has been approved by 17 countries so far. Covaccine thus joins World Health’s approved list of anti-COVID vaccines manufactured by Pfizer/BioNtech, Moderna, AstraZeneca, Johnson & Johnson, Sinopharm and Sinovac.


Show More

Related Articles

Leave a Reply

Back to top button